Chemotherapy News and Research

Latest Chemotherapy News and Research

Anti-aging drug combination causes brain damage in mice

A two-drug combination frequently used in anti-aging research causes brain damage in mice, University of Connecticut researchers report in the March 16 issue of PNAS.

17 Mar 2026

New CAR-T cell therapy shows promise for treating osteosarcoma

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has puzzled medical researchers for 40 years.

17 Mar 2026

Exercise cuts 'chemo brain' and fatigue in cancer patients

Implementing a simple exercise plan during chemotherapy may ease cognitive impairment and fatigue, promoting better health outcomes for cancer patients.

17 Mar 2026

New insight into origins of rare liver tumors in children

Liver cancer in children is rare, but when it occurs the two main types are hepatoblastoma (HB) and hepatocellular carcinoma (HCC).

16 Mar 2026

New CAR-NKT cell therapy shows promise against aggressive endometrial cancer

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades.

16 Mar 2026

Clinical trial tests a newer, targeted therapy for IDH mutant astrocytoma

A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies after radiation therapy improves outcomes for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma, a type of brain cancer.

16 Mar 2026

Exercise during chemotherapy supports physical and cognitive health

Researchers recommended a tailored, scientifically validated exercise program to individuals receiving chemotherapy for cancer, and those who were on a two-week chemotherapy schedule and followed the exercise prescription were able to maintain their walking-step goals, use resistance bands, and stay mentally sharper compared to patients who did not exercise.

13 Mar 2026

Researchers achieve breakthrough in the production of vital chemotherapy agent

An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent.

13 Mar 2026

Scientists win awards for the discovery of genomic imprinting and tumor’s power grid

For their discovery of genomic imprinting, developmental biologists Davor Solter and Azim Surani will receive the 2026 Paul Ehrlich and Ludwig Darmstaedter Prize, endowed with €120,000, on March 14 at Frankfurt’s Paulskirche.

13 Mar 2026

Defining the limits of immunotherapy in early small-cell lung cancer

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international clinical trial, NRG-LU005, led by NRG Oncology in collaboration with the Alliance for Clinical Trials in Oncology. The results are published in the Journal of Clinical Oncology.

13 Mar 2026

Topical cream activates immune response to suppress skin cancer growth

A topical cream activated the skin's immune defenses and suppressed tumor growth in two preclinical models of cutaneous squamous cell carcinoma (cSCC), one of the most common cancers in the world, according to a study published today in the Journal of Clinical Investigation.

12 Mar 2026

Romiplostim prevents chemotherapy-induced thrombocytopenia in phase 3 trial

Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication romiplostim can effectively prevent chemotherapy from destroying platelet-producing bone marrow cells, a common complication known as chemotherapy-induced thrombocytopenia.

12 Mar 2026

Structured exercise helps chemotherapy patients maintain cognitive function and mental clarity

New research in the March 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks, work, and social activities through chemotherapy treatment delivered on an every two-week cycle.

12 Mar 2026

Combat Medical raises £2.6 million Series A to advance treatment of BCG unresponsive bladder cancer

Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to advance its hyperthermic intravesical chemotherapy treatment, HIVEC® through phase 3 clinical trials and toward FDA registration.

From Combat Medical 12 Mar 2026

New protein target for safer lung cancer therapy

Researchers at the University of Gothenburg have identified a protein linked to an increased risk of metastasis and recurrence in lung cancer. The findings are presented in a study that paves the way for new precision medicine approaches, particularly for older patients.

12 Mar 2026